Optima Health (AIM:OPT) is pitched as a 'Buy' as stockbroker Panmure Liberum looks ahead to full-year results due next week (on 17 August).
Analyst Dr Julie Simmonds sees next week's update as a potential marker of progress following Optima's transformational acquisition of PAM Healthcare, completed on 26 March for approximately £100m.
The numbers cover the period leading up to the transaction, so they precede the deal's consolidation into the group's accounts.
Nevertheless, the Panmure Liberum analyst expects the update to address integration progress on PAM, the group's transformation programme, and the start of a substantial AFRS contract due to contribute at scale from April 2027.
Optima has already flagged £1.3m of annualised cost synergies delivered from the PAM tie-up as of 1 June, against reiterated medium-term targets of £200m revenue and £40m adjusted EBITDA.
The stockbroker sees scope for meaningful mid-term upside as Optima benefits from margin enhancement through scale, the transformation programme and further acquisitive growth.
In the market today, Optima is priced at around 252p.
